JP2012508016A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012508016A5 JP2012508016A5 JP2011535649A JP2011535649A JP2012508016A5 JP 2012508016 A5 JP2012508016 A5 JP 2012508016A5 JP 2011535649 A JP2011535649 A JP 2011535649A JP 2011535649 A JP2011535649 A JP 2011535649A JP 2012508016 A5 JP2012508016 A5 JP 2012508016A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- human
- germline
- antigen
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004602 germ cell Anatomy 0.000 claims 73
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 39
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 39
- 239000000427 antigen Substances 0.000 claims 39
- 102000036639 antigens Human genes 0.000 claims 39
- 108091007433 antigens Proteins 0.000 claims 39
- 230000027455 binding Effects 0.000 claims 37
- 108090000623 proteins and genes Proteins 0.000 claims 25
- -1 MMP inhibitor Proteins 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 102000000844 Cell Surface Receptors Human genes 0.000 claims 5
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 239000000816 peptidomimetic Substances 0.000 claims 5
- 230000005714 functional activity Effects 0.000 claims 4
- 102000001301 EGF receptor Human genes 0.000 claims 2
- 108060006698 EGF receptor Proteins 0.000 claims 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 2
- 101500026735 Homo sapiens Brain natriuretic peptide 32 Proteins 0.000 claims 2
- 101001079285 Homo sapiens Immunoglobulin heavy joining 1 Proteins 0.000 claims 2
- 101001091242 Homo sapiens Immunoglobulin kappa joining 1 Proteins 0.000 claims 2
- 101001138128 Homo sapiens Immunoglobulin kappa variable 1-12 Proteins 0.000 claims 2
- 101001138089 Homo sapiens Immunoglobulin kappa variable 1-39 Proteins 0.000 claims 2
- 101001047629 Homo sapiens Immunoglobulin kappa variable 2-30 Proteins 0.000 claims 2
- 101001134437 Homo sapiens Immunoglobulin lambda joining 1 Proteins 0.000 claims 2
- 101000978126 Homo sapiens Immunoglobulin lambda variable 8-61 Proteins 0.000 claims 2
- 102100028078 Immunoglobulin heavy joining 1 Human genes 0.000 claims 2
- 102100034892 Immunoglobulin kappa joining 1 Human genes 0.000 claims 2
- 102100020773 Immunoglobulin kappa variable 1-12 Human genes 0.000 claims 2
- 102100020910 Immunoglobulin kappa variable 1-39 Human genes 0.000 claims 2
- 102100022952 Immunoglobulin kappa variable 2-30 Human genes 0.000 claims 2
- 102100034172 Immunoglobulin lambda joining 1 Human genes 0.000 claims 2
- 102100023752 Immunoglobulin lambda variable 8-61 Human genes 0.000 claims 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims 2
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 claims 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 102100040843 C-type lectin domain family 4 member M Human genes 0.000 claims 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 1
- 102100032912 CD44 antigen Human genes 0.000 claims 1
- 108010065524 CD52 Antigen Proteins 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 102000000905 Cadherin Human genes 0.000 claims 1
- 108050007957 Cadherin Proteins 0.000 claims 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 102100033553 Delta-like protein 4 Human genes 0.000 claims 1
- 101150029707 ERBB2 gene Proteins 0.000 claims 1
- 108010092408 Eosinophil Peroxidase Proteins 0.000 claims 1
- 102100036509 Erythropoietin receptor Human genes 0.000 claims 1
- 101710102442 Erythropoietin receptor Proteins 0.000 claims 1
- 108010011459 Exenatide Proteins 0.000 claims 1
- 108010008177 Fd immunoglobulins Proteins 0.000 claims 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 1
- 102400000321 Glucagon Human genes 0.000 claims 1
- 108060003199 Glucagon Proteins 0.000 claims 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 1
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 claims 1
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 claims 1
- 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 claims 1
- 101710142125 Granulocyte colony-stimulating factor receptor Proteins 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000749311 Homo sapiens C-type lectin domain family 4 member M Proteins 0.000 claims 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 1
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 claims 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims 1
- 101000843762 Homo sapiens Immunoglobulin heavy diversity 1-1 Proteins 0.000 claims 1
- 101000998950 Homo sapiens Immunoglobulin heavy variable 1-18 Proteins 0.000 claims 1
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims 1
- 101000998949 Homo sapiens Immunoglobulin heavy variable 1-24 Proteins 0.000 claims 1
- 101000998952 Homo sapiens Immunoglobulin heavy variable 1-3 Proteins 0.000 claims 1
- 101000998948 Homo sapiens Immunoglobulin heavy variable 1-45 Proteins 0.000 claims 1
- 101000998947 Homo sapiens Immunoglobulin heavy variable 1-46 Proteins 0.000 claims 1
- 101001002931 Homo sapiens Immunoglobulin heavy variable 1-58 Proteins 0.000 claims 1
- 101001037147 Homo sapiens Immunoglobulin heavy variable 1-69 Proteins 0.000 claims 1
- 101000998951 Homo sapiens Immunoglobulin heavy variable 1-8 Proteins 0.000 claims 1
- 101001037152 Homo sapiens Immunoglobulin heavy variable 2-26 Proteins 0.000 claims 1
- 101001037145 Homo sapiens Immunoglobulin heavy variable 2-5 Proteins 0.000 claims 1
- 101001037151 Homo sapiens Immunoglobulin heavy variable 2-70 Proteins 0.000 claims 1
- 101001037138 Homo sapiens Immunoglobulin heavy variable 3-11 Proteins 0.000 claims 1
- 101001037137 Homo sapiens Immunoglobulin heavy variable 3-13 Proteins 0.000 claims 1
- 101001037136 Homo sapiens Immunoglobulin heavy variable 3-15 Proteins 0.000 claims 1
- 101001037142 Homo sapiens Immunoglobulin heavy variable 3-20 Proteins 0.000 claims 1
- 101001037141 Homo sapiens Immunoglobulin heavy variable 3-21 Proteins 0.000 claims 1
- 101001037140 Homo sapiens Immunoglobulin heavy variable 3-23 Proteins 0.000 claims 1
- 101001037139 Homo sapiens Immunoglobulin heavy variable 3-30 Proteins 0.000 claims 1
- 101001037143 Homo sapiens Immunoglobulin heavy variable 3-33 Proteins 0.000 claims 1
- 101000839665 Homo sapiens Immunoglobulin heavy variable 3-43 Proteins 0.000 claims 1
- 101000839662 Homo sapiens Immunoglobulin heavy variable 3-48 Proteins 0.000 claims 1
- 101000839663 Homo sapiens Immunoglobulin heavy variable 3-49 Proteins 0.000 claims 1
- 101000839660 Homo sapiens Immunoglobulin heavy variable 3-53 Proteins 0.000 claims 1
- 101000839661 Homo sapiens Immunoglobulin heavy variable 3-64 Proteins 0.000 claims 1
- 101000839658 Homo sapiens Immunoglobulin heavy variable 3-66 Proteins 0.000 claims 1
- 101001037153 Homo sapiens Immunoglobulin heavy variable 3-7 Proteins 0.000 claims 1
- 101000839659 Homo sapiens Immunoglobulin heavy variable 3-72 Proteins 0.000 claims 1
- 101000839657 Homo sapiens Immunoglobulin heavy variable 3-73 Proteins 0.000 claims 1
- 101000839687 Homo sapiens Immunoglobulin heavy variable 3-74 Proteins 0.000 claims 1
- 101001037144 Homo sapiens Immunoglobulin heavy variable 3-9 Proteins 0.000 claims 1
- 101000839683 Homo sapiens Immunoglobulin heavy variable 4-28 Proteins 0.000 claims 1
- 101000839684 Homo sapiens Immunoglobulin heavy variable 4-31 Proteins 0.000 claims 1
- 101000839682 Homo sapiens Immunoglobulin heavy variable 4-34 Proteins 0.000 claims 1
- 101000839679 Homo sapiens Immunoglobulin heavy variable 4-39 Proteins 0.000 claims 1
- 101000839686 Homo sapiens Immunoglobulin heavy variable 4-4 Proteins 0.000 claims 1
- 101000839781 Homo sapiens Immunoglobulin heavy variable 4-59 Proteins 0.000 claims 1
- 101000989076 Homo sapiens Immunoglobulin heavy variable 4-61 Proteins 0.000 claims 1
- 101000989062 Homo sapiens Immunoglobulin heavy variable 5-51 Proteins 0.000 claims 1
- 101000989060 Homo sapiens Immunoglobulin heavy variable 6-1 Proteins 0.000 claims 1
- 101001138126 Homo sapiens Immunoglobulin kappa variable 1-16 Proteins 0.000 claims 1
- 101001138125 Homo sapiens Immunoglobulin kappa variable 1-17 Proteins 0.000 claims 1
- 101001138123 Homo sapiens Immunoglobulin kappa variable 1-27 Proteins 0.000 claims 1
- 101001138121 Homo sapiens Immunoglobulin kappa variable 1-33 Proteins 0.000 claims 1
- 101001138133 Homo sapiens Immunoglobulin kappa variable 1-5 Proteins 0.000 claims 1
- 101001138132 Homo sapiens Immunoglobulin kappa variable 1-6 Proteins 0.000 claims 1
- 101001138131 Homo sapiens Immunoglobulin kappa variable 1-8 Proteins 0.000 claims 1
- 101001138130 Homo sapiens Immunoglobulin kappa variable 1-9 Proteins 0.000 claims 1
- 101001008259 Homo sapiens Immunoglobulin kappa variable 1D-12 Proteins 0.000 claims 1
- 101001008261 Homo sapiens Immunoglobulin kappa variable 1D-13 Proteins 0.000 claims 1
- 101001008333 Homo sapiens Immunoglobulin kappa variable 1D-16 Proteins 0.000 claims 1
- 101001008329 Homo sapiens Immunoglobulin kappa variable 1D-33 Proteins 0.000 claims 1
- 101001008313 Homo sapiens Immunoglobulin kappa variable 1D-39 Proteins 0.000 claims 1
- 101001009877 Homo sapiens Immunoglobulin kappa variable 1D-43 Proteins 0.000 claims 1
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 claims 1
- 101001047626 Homo sapiens Immunoglobulin kappa variable 2-24 Proteins 0.000 claims 1
- 101001047627 Homo sapiens Immunoglobulin kappa variable 2-28 Proteins 0.000 claims 1
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 claims 1
- 101001047625 Homo sapiens Immunoglobulin kappa variable 2-40 Proteins 0.000 claims 1
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 claims 1
- 101001008323 Homo sapiens Immunoglobulin kappa variable 2D-28 Proteins 0.000 claims 1
- 101001008325 Homo sapiens Immunoglobulin kappa variable 2D-29 Proteins 0.000 claims 1
- 101001008293 Homo sapiens Immunoglobulin kappa variable 2D-40 Proteins 0.000 claims 1
- 101001047617 Homo sapiens Immunoglobulin kappa variable 3-11 Proteins 0.000 claims 1
- 101001047618 Homo sapiens Immunoglobulin kappa variable 3-15 Proteins 0.000 claims 1
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims 1
- 101001008257 Homo sapiens Immunoglobulin kappa variable 3D-11 Proteins 0.000 claims 1
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 claims 1
- 101001008315 Homo sapiens Immunoglobulin kappa variable 3D-20 Proteins 0.000 claims 1
- 101000604674 Homo sapiens Immunoglobulin kappa variable 4-1 Proteins 0.000 claims 1
- 101000605181 Homo sapiens Immunoglobulin kappa variable 5-2 Proteins 0.000 claims 1
- 101001090250 Homo sapiens Immunoglobulin kappa variable 6-21 Proteins 0.000 claims 1
- 101001008317 Homo sapiens Immunoglobulin kappa variable 6D-21 Proteins 0.000 claims 1
- 101001054844 Homo sapiens Immunoglobulin lambda variable 1-36 Proteins 0.000 claims 1
- 101001054843 Homo sapiens Immunoglobulin lambda variable 1-40 Proteins 0.000 claims 1
- 101001054838 Homo sapiens Immunoglobulin lambda variable 1-44 Proteins 0.000 claims 1
- 101001054837 Homo sapiens Immunoglobulin lambda variable 1-47 Proteins 0.000 claims 1
- 101001054839 Homo sapiens Immunoglobulin lambda variable 1-51 Proteins 0.000 claims 1
- 101000578462 Homo sapiens Immunoglobulin lambda variable 10-54 Proteins 0.000 claims 1
- 101000956884 Homo sapiens Immunoglobulin lambda variable 2-11 Proteins 0.000 claims 1
- 101000956885 Homo sapiens Immunoglobulin lambda variable 2-14 Proteins 0.000 claims 1
- 101000956888 Homo sapiens Immunoglobulin lambda variable 2-18 Proteins 0.000 claims 1
- 101000956889 Homo sapiens Immunoglobulin lambda variable 2-23 Proteins 0.000 claims 1
- 101000956887 Homo sapiens Immunoglobulin lambda variable 2-8 Proteins 0.000 claims 1
- 101001005360 Homo sapiens Immunoglobulin lambda variable 3-1 Proteins 0.000 claims 1
- 101001005361 Homo sapiens Immunoglobulin lambda variable 3-10 Proteins 0.000 claims 1
- 101001005362 Homo sapiens Immunoglobulin lambda variable 3-12 Proteins 0.000 claims 1
- 101001005363 Homo sapiens Immunoglobulin lambda variable 3-16 Proteins 0.000 claims 1
- 101001005364 Homo sapiens Immunoglobulin lambda variable 3-19 Proteins 0.000 claims 1
- 101001005365 Homo sapiens Immunoglobulin lambda variable 3-21 Proteins 0.000 claims 1
- 101001005366 Homo sapiens Immunoglobulin lambda variable 3-22 Proteins 0.000 claims 1
- 101001005336 Homo sapiens Immunoglobulin lambda variable 3-25 Proteins 0.000 claims 1
- 101001005337 Homo sapiens Immunoglobulin lambda variable 3-27 Proteins 0.000 claims 1
- 101001005329 Homo sapiens Immunoglobulin lambda variable 3-9 Proteins 0.000 claims 1
- 101001005330 Homo sapiens Immunoglobulin lambda variable 4-3 Proteins 0.000 claims 1
- 101001005331 Homo sapiens Immunoglobulin lambda variable 4-60 Proteins 0.000 claims 1
- 101001005332 Homo sapiens Immunoglobulin lambda variable 4-69 Proteins 0.000 claims 1
- 101001005333 Homo sapiens Immunoglobulin lambda variable 5-37 Proteins 0.000 claims 1
- 101001005334 Homo sapiens Immunoglobulin lambda variable 5-39 Proteins 0.000 claims 1
- 101001005335 Homo sapiens Immunoglobulin lambda variable 5-45 Proteins 0.000 claims 1
- 101000978130 Homo sapiens Immunoglobulin lambda variable 5-52 Proteins 0.000 claims 1
- 101000978133 Homo sapiens Immunoglobulin lambda variable 6-57 Proteins 0.000 claims 1
- 101000978132 Homo sapiens Immunoglobulin lambda variable 7-43 Proteins 0.000 claims 1
- 101000978127 Homo sapiens Immunoglobulin lambda variable 7-46 Proteins 0.000 claims 1
- 101000978129 Homo sapiens Immunoglobulin lambda variable 9-49 Proteins 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims 1
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 claims 1
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 claims 1
- 101001037135 Homo sapiens Probable non-functional immunoglobulin heavy variable 3-16 Proteins 0.000 claims 1
- 101001037134 Homo sapiens Probable non-functional immunoglobulin heavy variable 3-35 Proteins 0.000 claims 1
- 101000839664 Homo sapiens Probable non-functional immunoglobulin heavy variable 3-38 Proteins 0.000 claims 1
- 101000989063 Homo sapiens Probable non-functional immunoglobulin heavy variable 7-81 Proteins 0.000 claims 1
- 101001009876 Homo sapiens Probable non-functional immunoglobulin kappa variable 1D-42 Proteins 0.000 claims 1
- 101001008319 Homo sapiens Probable non-functional immunoglobulin kappa variable 2D-24 Proteins 0.000 claims 1
- 101001047520 Homo sapiens Probable non-functional immunoglobulin kappa variable 3-7 Proteins 0.000 claims 1
- 101001009875 Homo sapiens Probable non-functional immunoglobulin kappa variable 6D-41 Proteins 0.000 claims 1
- 101001054840 Homo sapiens Probable non-functional immunoglobulin lambda variable 1-50 Proteins 0.000 claims 1
- 101000978120 Homo sapiens Probable non-functional immunoglobulin lambda variable 11-55 Proteins 0.000 claims 1
- 101000956613 Homo sapiens Probable non-functional immunoglobulin lambda variable 2-33 Proteins 0.000 claims 1
- 101001005338 Homo sapiens Probable non-functional immunoglobulin lambda variable 3-32 Proteins 0.000 claims 1
- 101001138120 Homo sapiens Probable non-functional immunoglobulinn kappa variable 1-37 Proteins 0.000 claims 1
- 101001008331 Homo sapiens Probable non-functional immunoglobulinn kappa variable 1D-37 Proteins 0.000 claims 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 claims 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 102100030644 Immunoglobulin heavy diversity 1-1 Human genes 0.000 claims 1
- 102100036884 Immunoglobulin heavy variable 1-18 Human genes 0.000 claims 1
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims 1
- 102100036890 Immunoglobulin heavy variable 1-24 Human genes 0.000 claims 1
- 102100036886 Immunoglobulin heavy variable 1-3 Human genes 0.000 claims 1
- 102100036889 Immunoglobulin heavy variable 1-45 Human genes 0.000 claims 1
- 102100036888 Immunoglobulin heavy variable 1-46 Human genes 0.000 claims 1
- 102100020774 Immunoglobulin heavy variable 1-58 Human genes 0.000 claims 1
- 102100040232 Immunoglobulin heavy variable 1-69 Human genes 0.000 claims 1
- 102100036885 Immunoglobulin heavy variable 1-8 Human genes 0.000 claims 1
- 102100040230 Immunoglobulin heavy variable 2-26 Human genes 0.000 claims 1
- 102100040235 Immunoglobulin heavy variable 2-5 Human genes 0.000 claims 1
- 102100040233 Immunoglobulin heavy variable 2-70 Human genes 0.000 claims 1
- 102100040222 Immunoglobulin heavy variable 3-11 Human genes 0.000 claims 1
- 102100040221 Immunoglobulin heavy variable 3-13 Human genes 0.000 claims 1
- 102100040224 Immunoglobulin heavy variable 3-15 Human genes 0.000 claims 1
- 102100040218 Immunoglobulin heavy variable 3-20 Human genes 0.000 claims 1
- 102100040217 Immunoglobulin heavy variable 3-21 Human genes 0.000 claims 1
- 102100040220 Immunoglobulin heavy variable 3-23 Human genes 0.000 claims 1
- 102100040219 Immunoglobulin heavy variable 3-30 Human genes 0.000 claims 1
- 102100040236 Immunoglobulin heavy variable 3-33 Human genes 0.000 claims 1
- 102100028315 Immunoglobulin heavy variable 3-43 Human genes 0.000 claims 1
- 102100028320 Immunoglobulin heavy variable 3-48 Human genes 0.000 claims 1
- 102100028319 Immunoglobulin heavy variable 3-49 Human genes 0.000 claims 1
- 102100028317 Immunoglobulin heavy variable 3-53 Human genes 0.000 claims 1
- 102100028321 Immunoglobulin heavy variable 3-64 Human genes 0.000 claims 1
- 102100027821 Immunoglobulin heavy variable 3-66 Human genes 0.000 claims 1
- 102100040231 Immunoglobulin heavy variable 3-7 Human genes 0.000 claims 1
- 102100027820 Immunoglobulin heavy variable 3-72 Human genes 0.000 claims 1
- 102100027822 Immunoglobulin heavy variable 3-73 Human genes 0.000 claims 1
- 102100028305 Immunoglobulin heavy variable 3-74 Human genes 0.000 claims 1
- 102100040234 Immunoglobulin heavy variable 3-9 Human genes 0.000 claims 1
- 102100028311 Immunoglobulin heavy variable 4-28 Human genes 0.000 claims 1
- 102100028310 Immunoglobulin heavy variable 4-31 Human genes 0.000 claims 1
- 102100028306 Immunoglobulin heavy variable 4-34 Human genes 0.000 claims 1
- 102100028312 Immunoglobulin heavy variable 4-39 Human genes 0.000 claims 1
- 102100028308 Immunoglobulin heavy variable 4-4 Human genes 0.000 claims 1
- 102100028405 Immunoglobulin heavy variable 4-59 Human genes 0.000 claims 1
- 102100029419 Immunoglobulin heavy variable 4-61 Human genes 0.000 claims 1
- 102100029414 Immunoglobulin heavy variable 5-51 Human genes 0.000 claims 1
- 102100029416 Immunoglobulin heavy variable 6-1 Human genes 0.000 claims 1
- 102100020946 Immunoglobulin kappa variable 1-16 Human genes 0.000 claims 1
- 102100020945 Immunoglobulin kappa variable 1-17 Human genes 0.000 claims 1
- 102100020902 Immunoglobulin kappa variable 1-27 Human genes 0.000 claims 1
- 102100020901 Immunoglobulin kappa variable 1-33 Human genes 0.000 claims 1
- 102100020769 Immunoglobulin kappa variable 1-5 Human genes 0.000 claims 1
- 102100020768 Immunoglobulin kappa variable 1-6 Human genes 0.000 claims 1
- 102100020771 Immunoglobulin kappa variable 1-8 Human genes 0.000 claims 1
- 102100020770 Immunoglobulin kappa variable 1-9 Human genes 0.000 claims 1
- 102100027412 Immunoglobulin kappa variable 1D-12 Human genes 0.000 claims 1
- 102100027411 Immunoglobulin kappa variable 1D-13 Human genes 0.000 claims 1
- 102100027462 Immunoglobulin kappa variable 1D-16 Human genes 0.000 claims 1
- 102100027464 Immunoglobulin kappa variable 1D-33 Human genes 0.000 claims 1
- 102100027404 Immunoglobulin kappa variable 1D-39 Human genes 0.000 claims 1
- 102100030883 Immunoglobulin kappa variable 1D-43 Human genes 0.000 claims 1
- 102100027406 Immunoglobulin kappa variable 1D-8 Human genes 0.000 claims 1
- 102100022947 Immunoglobulin kappa variable 2-24 Human genes 0.000 claims 1
- 102100022950 Immunoglobulin kappa variable 2-28 Human genes 0.000 claims 1
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 claims 1
- 102100022948 Immunoglobulin kappa variable 2-40 Human genes 0.000 claims 1
- 102100027460 Immunoglobulin kappa variable 2D-26 Human genes 0.000 claims 1
- 102100027459 Immunoglobulin kappa variable 2D-28 Human genes 0.000 claims 1
- 102100027458 Immunoglobulin kappa variable 2D-29 Human genes 0.000 claims 1
- 102100027409 Immunoglobulin kappa variable 2D-40 Human genes 0.000 claims 1
- 102100022955 Immunoglobulin kappa variable 3-11 Human genes 0.000 claims 1
- 102100022965 Immunoglobulin kappa variable 3-15 Human genes 0.000 claims 1
- 102100022964 Immunoglobulin kappa variable 3-20 Human genes 0.000 claims 1
- 102100027405 Immunoglobulin kappa variable 3D-11 Human genes 0.000 claims 1
- 102100027410 Immunoglobulin kappa variable 3D-15 Human genes 0.000 claims 1
- 102100027403 Immunoglobulin kappa variable 3D-20 Human genes 0.000 claims 1
- 102100038198 Immunoglobulin kappa variable 4-1 Human genes 0.000 claims 1
- 102100038241 Immunoglobulin kappa variable 5-2 Human genes 0.000 claims 1
- 102100034806 Immunoglobulin kappa variable 6-21 Human genes 0.000 claims 1
- 102100027402 Immunoglobulin kappa variable 6D-21 Human genes 0.000 claims 1
- 102100026916 Immunoglobulin lambda variable 1-36 Human genes 0.000 claims 1
- 102100026911 Immunoglobulin lambda variable 1-40 Human genes 0.000 claims 1
- 102100026921 Immunoglobulin lambda variable 1-44 Human genes 0.000 claims 1
- 102100026809 Immunoglobulin lambda variable 1-47 Human genes 0.000 claims 1
- 102100026922 Immunoglobulin lambda variable 1-51 Human genes 0.000 claims 1
- 102100027972 Immunoglobulin lambda variable 10-54 Human genes 0.000 claims 1
- 102100038432 Immunoglobulin lambda variable 2-11 Human genes 0.000 claims 1
- 102100038429 Immunoglobulin lambda variable 2-14 Human genes 0.000 claims 1
- 102100038431 Immunoglobulin lambda variable 2-18 Human genes 0.000 claims 1
- 102100038430 Immunoglobulin lambda variable 2-23 Human genes 0.000 claims 1
- 102100038428 Immunoglobulin lambda variable 2-8 Human genes 0.000 claims 1
- 102100025921 Immunoglobulin lambda variable 3-1 Human genes 0.000 claims 1
- 102100025919 Immunoglobulin lambda variable 3-10 Human genes 0.000 claims 1
- 102100025920 Immunoglobulin lambda variable 3-12 Human genes 0.000 claims 1
- 102100025936 Immunoglobulin lambda variable 3-16 Human genes 0.000 claims 1
- 102100025937 Immunoglobulin lambda variable 3-19 Human genes 0.000 claims 1
- 102100025934 Immunoglobulin lambda variable 3-21 Human genes 0.000 claims 1
- 102100025935 Immunoglobulin lambda variable 3-22 Human genes 0.000 claims 1
- 102100025876 Immunoglobulin lambda variable 3-25 Human genes 0.000 claims 1
- 102100025874 Immunoglobulin lambda variable 3-27 Human genes 0.000 claims 1
- 102100025864 Immunoglobulin lambda variable 3-9 Human genes 0.000 claims 1
- 102100025865 Immunoglobulin lambda variable 4-3 Human genes 0.000 claims 1
- 102100025862 Immunoglobulin lambda variable 4-60 Human genes 0.000 claims 1
- 102100025863 Immunoglobulin lambda variable 4-69 Human genes 0.000 claims 1
- 102100025856 Immunoglobulin lambda variable 5-37 Human genes 0.000 claims 1
- 102100025857 Immunoglobulin lambda variable 5-39 Human genes 0.000 claims 1
- 102100025855 Immunoglobulin lambda variable 5-45 Human genes 0.000 claims 1
- 102100023753 Immunoglobulin lambda variable 5-52 Human genes 0.000 claims 1
- 102100023747 Immunoglobulin lambda variable 6-57 Human genes 0.000 claims 1
- 102100023746 Immunoglobulin lambda variable 7-43 Human genes 0.000 claims 1
- 102100023751 Immunoglobulin lambda variable 7-46 Human genes 0.000 claims 1
- 102100023754 Immunoglobulin lambda variable 9-49 Human genes 0.000 claims 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 229940124761 MMP inhibitor Drugs 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000014736 Notch Human genes 0.000 claims 1
- 108010070047 Notch Receptors Proteins 0.000 claims 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 claims 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims 1
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 claims 1
- 102400000979 Pituitary adenylate cyclase-activating polypeptide 38 Human genes 0.000 claims 1
- 102100035194 Placenta growth factor Human genes 0.000 claims 1
- 102100033237 Pro-epidermal growth factor Human genes 0.000 claims 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims 1
- 102100040918 Pro-glucagon Human genes 0.000 claims 1
- 102100040223 Probable non-functional immunoglobulin heavy variable 3-16 Human genes 0.000 claims 1
- 102100040226 Probable non-functional immunoglobulin heavy variable 3-35 Human genes 0.000 claims 1
- 102100028318 Probable non-functional immunoglobulin heavy variable 3-38 Human genes 0.000 claims 1
- 102100029413 Probable non-functional immunoglobulin heavy variable 7-81 Human genes 0.000 claims 1
- 102100030884 Probable non-functional immunoglobulin kappa variable 1D-42 Human genes 0.000 claims 1
- 102100027461 Probable non-functional immunoglobulin kappa variable 2D-24 Human genes 0.000 claims 1
- 102100022959 Probable non-functional immunoglobulin kappa variable 3-7 Human genes 0.000 claims 1
- 102100030885 Probable non-functional immunoglobulin kappa variable 6D-41 Human genes 0.000 claims 1
- 102100026912 Probable non-functional immunoglobulin lambda variable 1-50 Human genes 0.000 claims 1
- 102100023451 Probable non-functional immunoglobulin lambda variable 11-55 Human genes 0.000 claims 1
- 102100038489 Probable non-functional immunoglobulin lambda variable 2-33 Human genes 0.000 claims 1
- 102100025868 Probable non-functional immunoglobulin lambda variable 3-32 Human genes 0.000 claims 1
- 102100020904 Probable non-functional immunoglobulinn kappa variable 1-37 Human genes 0.000 claims 1
- 102100027463 Probable non-functional immunoglobulinn kappa variable 1D-37 Human genes 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 108091005682 Receptor kinases Proteins 0.000 claims 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 1
- 101710113649 Thyroid peroxidase Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 1
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims 1
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 1
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 claims 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims 1
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 claims 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 claims 1
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 claims 1
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 claims 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000004709 cell invasion Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 claims 1
- 230000035605 chemotaxis Effects 0.000 claims 1
- 108010057085 cytokine receptors Proteins 0.000 claims 1
- 102000003675 cytokine receptors Human genes 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 229960001519 exenatide Drugs 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 1
- 229960004666 glucagon Drugs 0.000 claims 1
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 230000008611 intercellular interaction Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108010082117 matrigel Proteins 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- UFTCZKMBJOPXDM-XXFCQBPRSA-N pituitary adenylate cyclase-activating polypeptide Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 UFTCZKMBJOPXDM-XXFCQBPRSA-N 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19876408P | 2008-11-07 | 2008-11-07 | |
| US61/198,764 | 2008-11-07 | ||
| US21120409P | 2009-03-25 | 2009-03-25 | |
| US61/211,204 | 2009-03-25 | ||
| PCT/US2009/063299 WO2010054007A1 (en) | 2008-11-07 | 2009-11-04 | Combinatorial antibody libraries and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016018531A Division JP2016127850A (ja) | 2008-11-07 | 2016-02-03 | 組合せ抗体ライブラリー及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012508016A JP2012508016A (ja) | 2012-04-05 |
| JP2012508016A5 true JP2012508016A5 (OSRAM) | 2013-01-24 |
| JP5882058B2 JP5882058B2 (ja) | 2016-03-09 |
Family
ID=41508157
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011535649A Expired - Fee Related JP5882058B2 (ja) | 2008-11-07 | 2009-11-04 | 組合せ抗体ライブラリー及びその使用 |
| JP2011535651A Pending JP2012508017A (ja) | 2008-11-07 | 2009-11-04 | 抗ｄｌｌ４抗体及びその使用 |
| JP2015157842A Pending JP2016040246A (ja) | 2008-11-07 | 2015-08-10 | 抗ｄｌｌ４抗体及びその使用 |
| JP2016018531A Pending JP2016127850A (ja) | 2008-11-07 | 2016-02-03 | 組合せ抗体ライブラリー及びその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011535651A Pending JP2012508017A (ja) | 2008-11-07 | 2009-11-04 | 抗ｄｌｌ４抗体及びその使用 |
| JP2015157842A Pending JP2016040246A (ja) | 2008-11-07 | 2015-08-10 | 抗ｄｌｌ４抗体及びその使用 |
| JP2016018531A Pending JP2016127850A (ja) | 2008-11-07 | 2016-02-03 | 組合せ抗体ライブラリー及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US9403904B2 (OSRAM) |
| EP (2) | EP2356270B1 (OSRAM) |
| JP (4) | JP5882058B2 (OSRAM) |
| AU (4) | AU2009313551B2 (OSRAM) |
| CA (2) | CA2742968C (OSRAM) |
| DK (1) | DK2356270T3 (OSRAM) |
| WO (2) | WO2010054010A1 (OSRAM) |
Families Citing this family (205)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9567396B2 (en) | 2006-03-07 | 2017-02-14 | Evonik Degussa Gmbh | Notch inhibition in the prevention of vein graft failure |
| HUE028379T2 (en) | 2006-09-29 | 2016-12-28 | Oncomed Pharm Inc | Preparations and procedures for the diagnosis and treatment of cancer |
| JP5591691B2 (ja) | 2007-05-22 | 2014-09-17 | アムジエン・インコーポレーテツド | 生物活性を有する融合タンパク質を作製するための組成物及び方法 |
| EA201001467A1 (ru) | 2008-03-14 | 2011-06-30 | Биокон Лимитед | Моноклональное антитело и способ его использования |
| DK2356270T3 (da) | 2008-11-07 | 2016-12-12 | Fabrus Llc | Kombinatoriske antistofbiblioteker og anvendelser deraf |
| US8734796B2 (en) | 2009-03-20 | 2014-05-27 | Amgen Inc. | Carrier immunoglobulins |
| US20120100999A1 (en) * | 2009-04-20 | 2012-04-26 | University Health Network | Prognostic gene expression signature for squamous cell carcinoma of the lung |
| AU2010252939B2 (en) | 2009-05-29 | 2014-06-26 | Morphosys Ag | A collection and methods for its use |
| TWI513465B (zh) * | 2009-06-25 | 2015-12-21 | Regeneron Pharma | 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法 |
| ES2895226T3 (es) | 2009-10-16 | 2022-02-18 | Mereo Biopharma 5 Inc | Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensivos |
| EP2493497A4 (en) | 2009-11-01 | 2013-07-24 | Brigham & Womens Hospital | NOTCH INHIBITION IN THE TREATMENT AND PROPHYLAXIS OF ADIPOSITAS AND METABOLISM SYNDROME |
| WO2011056997A1 (en) | 2009-11-04 | 2011-05-12 | Fabrus Llc | Methods for affinity maturation-based antibody optimization |
| UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
| US10016620B2 (en) * | 2010-02-04 | 2018-07-10 | Procept Biorobotics Incorporation | Tissue sampling and cancer treatment apparatus |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| US20120021409A1 (en) * | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| DK2505654T4 (da) | 2010-02-08 | 2020-07-27 | Regeneron Pharma | Mus med fælles letkæde |
| JP6266343B2 (ja) | 2010-07-16 | 2018-01-24 | アディマブ， エルエルシー | 抗体ライブラリー |
| RU2598711C2 (ru) * | 2010-07-22 | 2016-09-27 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Антитело к противоопухолевому антигену и способы применения |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| EA201370076A1 (ru) | 2010-09-22 | 2013-08-30 | Амген Инк. | Иммуноглобулины-переносчики и их применение |
| EP2640742B1 (en) | 2010-11-19 | 2018-08-15 | MorphoSys AG | A collection of antibody sequences its use |
| US20160272697A2 (en) * | 2011-04-28 | 2016-09-22 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Neutralizing Antibodies to Nipah and Hendra Virus |
| DK2702146T3 (en) * | 2011-04-28 | 2019-03-11 | Univ Leland Stanford Junior | IDENTIFICATION OF POLYNUCLEOTIDES CONNECTED WITH A SAMPLE |
| KR101641057B1 (ko) | 2011-05-04 | 2016-07-20 | 오메로스 코포레이션 | Masp-2 의존적 보체 활성화를 억제하는 조성물 |
| KR101629073B1 (ko) * | 2011-06-15 | 2016-06-09 | 에프. 호프만-라 로슈 아게 | 항-인간 에리스로포이에틴 수용체 항체 및 이의 사용 방법 |
| MY172718A (en) | 2011-08-05 | 2019-12-11 | Regeneron Pharma | Humanized universal light chain mice |
| CN103890246A (zh) | 2011-08-18 | 2014-06-25 | 亲和生物科学公司 | 可溶性多肽 |
| PT2758073T (pt) | 2011-09-23 | 2019-02-01 | Oncomed Pharm Inc | Agentes de ligação a vegf/dll4 e utilizações dos mesmos |
| AU2012332587B2 (en) | 2011-11-01 | 2017-02-23 | Bionomics, Inc. | Antibodies and methods of treating cancer |
| AU2012332588B2 (en) | 2011-11-01 | 2017-09-07 | Bionomics, Inc. | Methods of blocking cancer stem cell growth |
| WO2013106485A2 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
| JP2015509091A (ja) | 2012-01-09 | 2015-03-26 | ザ スクリプス リサーチ インスティテュート | ヒト化抗体 |
| HUE056335T2 (hu) | 2012-01-31 | 2022-02-28 | Regeneron Pharma | ASIC1-ellenes antitestek és alkalmazásaik |
| WO2013131074A1 (en) * | 2012-03-02 | 2013-09-06 | Diogenix, Inc. | Methods and reagents for evaluating autoimmune disease and determining antibody repertoire |
| CA2866612C (en) | 2012-03-08 | 2018-01-16 | Halozyme, Inc. | Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof |
| CN104994872B (zh) | 2012-06-21 | 2018-09-14 | 索伦托治疗有限公司 | 与igf1r结合的抗原结合蛋白 |
| KR101535341B1 (ko) * | 2012-07-02 | 2015-07-13 | 한화케미칼 주식회사 | Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도 |
| US9777067B2 (en) | 2012-09-27 | 2017-10-03 | Massachusetts Institute Of Technology | HER2- and VEGF-A-binding proteins with enhanced stability |
| US9309318B2 (en) * | 2012-10-17 | 2016-04-12 | Amgen, Inc. | Compositions relating to anti-IL-21 receptor antibodies |
| EP2914961A4 (en) * | 2012-10-31 | 2016-04-20 | Oncomed Pharm Inc | METHODS AND MONITORING A TREATMENT BY AN ANTAGONIST OF DLL4 |
| BR112015010240A2 (pt) * | 2012-11-06 | 2017-08-22 | Medimmune Ltd | Terapias de combinação através do uso de mo-léculas de ligação de psl e de pcrv anti-pseudomonas |
| US10407503B2 (en) * | 2012-11-30 | 2019-09-10 | The Regents Of The University Of California | Fully human antibodies and fragments recognizing human c-Met |
| KR102233664B1 (ko) | 2012-12-05 | 2021-04-02 | 노파르티스 아게 | Epo를 표적화하는 항체에 대한 조성물 및 방법 |
| SG11201505663YA (en) * | 2013-01-24 | 2015-08-28 | Scripps Korea Antibody Inst | Protein combination-based fv library, and preparation method therefor |
| DK2989239T4 (da) * | 2013-04-25 | 2025-04-07 | Sutro Biopharma Inc | Selektion af Fab-fragmenter ved anvendelse af ribosomfremvisningsteknologi |
| WO2014176439A1 (en) | 2013-04-25 | 2014-10-30 | Sutro Biopharma, Inc. | The use of lambda-gam protein in ribosomal display technology |
| RU2539752C2 (ru) * | 2013-05-23 | 2015-01-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | ГУМАНИЗИРОВАННОЕ АНТИТЕЛО И АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ (Fab), СВЯЗЫВАЮЩИЕСЯ С ИНТЕРФЕРОНОМ- γ ЧЕЛОВЕКА, ФРАГМЕНТЫ ДНК, КОДИРУЮЩИЕ УКАЗАННОЕ АНТИТЕЛО И АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ, КЛЕТКА, ТРАНСФОРМИРОВАННАЯ ФРАГМЕНТОМ ДНК, И СПОСОБ ПОЛУЧЕНИЯ УКАЗАННОГО АНТИТЕЛА И АНТИГЕНСВЯЗЫВАЮЩЕГО ФРАГМЕНТА |
| US10208125B2 (en) * | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| US20160168231A1 (en) | 2013-07-18 | 2016-06-16 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
| US10640574B2 (en) | 2013-07-18 | 2020-05-05 | Taurus Biosciences, Llc | Humanized antibodies with ultralong complementary determining regions |
| LT3052192T (lt) * | 2013-10-02 | 2020-12-10 | Medimmune, Llc | Neutralizuojantys antikūnai prieš gripą a ir jų naudojimas |
| WO2015057906A1 (en) * | 2013-10-16 | 2015-04-23 | Janssen Biotech, Inc. | Cd200 receptor 1 agonists |
| GB201403775D0 (en) * | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| CN106103730B (zh) | 2014-03-14 | 2021-06-08 | 豪夫迈·罗氏有限公司 | 用于分泌异源多肽的方法和组合物 |
| BR112016021572A2 (pt) | 2014-03-21 | 2017-10-03 | Regeneron Pharma | Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação |
| CN112759650B (zh) | 2014-04-03 | 2024-10-01 | Igm生物科学股份有限公司 | 修饰的j链 |
| EP3126397B1 (en) * | 2014-04-04 | 2020-01-29 | Bionomics, Inc. | Humanized antibodies that bind lgr5 |
| GB201407852D0 (en) | 2014-05-02 | 2014-06-18 | Iontas Ltd | Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules |
| ES2782083T3 (es) * | 2014-06-24 | 2020-09-10 | Procept Biorobotics Corp | Aparato de muestreo de tejidos y tratamiento del cáncer |
| AU2015289805B2 (en) | 2014-07-15 | 2020-06-25 | Humabs Biomed Sa | Neutralizing anti-influenza B antibodies and uses thereof |
| EA201790489A1 (ru) * | 2014-08-29 | 2017-08-31 | Сорренто Терапьютикс, Инк. | ТЕРАПЕВТИЧЕСКИЕ СРЕДСТВА НА ОСНОВЕ АНТИТЕЛ, СВЯЗЫВАЮЩИЕ OprF И OprI |
| GB201419094D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-TIM-3-antibodies |
| CN107405397B (zh) | 2014-10-27 | 2020-08-25 | 新加坡科技研究局 | 抗tim-3抗体 |
| AU2015338974B2 (en) | 2014-10-31 | 2021-08-26 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| EA201791050A1 (ru) | 2014-11-14 | 2017-09-29 | Новартис Аг | Конъюгаты антител и лекарственных средств |
| EP3026060A1 (en) * | 2014-11-26 | 2016-06-01 | Miltenyi Biotec GmbH | Humanized antibody or fragment thereof specific for CD45R0 |
| EP3227432B1 (en) | 2014-12-05 | 2023-10-11 | Memorial Sloan Kettering Cancer Center | Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof |
| KR102701479B1 (ko) | 2014-12-05 | 2024-09-03 | 메모리얼 슬로안 케터링 캔서 센터 | B-세포 성숙화 항원을 표적화하는 항체 및 사용 방법 |
| EP3246434A1 (en) * | 2015-01-13 | 2017-11-22 | Ewha University-Industry Collaboration Foundation | Method for preparing novel antibody library and library prepared thereby |
| CN108025063A (zh) | 2015-03-10 | 2018-05-11 | 索伦托治疗有限公司 | 结合psma的抗体治疗剂 |
| CA2979702A1 (en) | 2015-03-19 | 2016-09-22 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
| CN107921122B (zh) | 2015-04-08 | 2021-08-10 | 索伦托药业有限公司 | 与cd38结合的抗体治疗剂 |
| PT3283524T (pt) | 2015-04-17 | 2023-06-05 | Amgen Res Munich Gmbh | Construções de anticorpos biespecíficos para cdh3 e cd3 |
| PH12017502013B1 (en) | 2015-05-07 | 2022-07-22 | Agenus Inc | Anti-ox40 antibodies and methods of use thereof |
| EP3297663B1 (en) | 2015-05-18 | 2025-11-12 | Agensys, Inc. | Antibodies that bind to axl proteins |
| WO2016187354A1 (en) * | 2015-05-18 | 2016-11-24 | Agensys, Inc. | Antibodies that bind to axl proteins |
| PL3303384T3 (pl) | 2015-06-01 | 2022-01-03 | Medimmune, Llc | Neutralizujące cząsteczki wiążące przeciw grypie i ich zastosowania |
| WO2017008049A1 (en) * | 2015-07-08 | 2017-01-12 | The Board Of Trustees Of The Leland Stanford Junior University | Heterotypic antibodies specific for human rotavirus |
| CN107922975B (zh) | 2015-08-12 | 2022-06-28 | 诺华股份有限公司 | 治疗眼科病症的方法 |
| US11339213B2 (en) | 2015-09-23 | 2022-05-24 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
| ES2996834T3 (en) | 2015-09-30 | 2025-02-13 | Igm Biosciences Inc | Binding molecules with modified j-chain |
| EP3356401B1 (en) | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| TWI752920B (zh) | 2015-10-12 | 2022-01-21 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| EP3184547A1 (en) * | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
| TWI726936B (zh) | 2015-11-10 | 2021-05-11 | 美商麥迪紐有限責任公司 | 對asct2具專一性之結合分子及其用途 |
| EP3383914A4 (en) * | 2015-12-02 | 2019-10-30 | Agenus Inc. | ANTI-OX40 ANTIBODIES AND METHOD OF USE THEREOF |
| SG11201804265XA (en) | 2015-12-02 | 2018-06-28 | Agenus Inc | Antibodies and methods of use thereof |
| WO2017096182A1 (en) * | 2015-12-03 | 2017-06-08 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
| CN106939047B (zh) | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
| CN105693821A (zh) * | 2016-01-08 | 2016-06-22 | 中国药科大学 | 与人血管内皮生长因子受体-3(vegfr-3)蛋白特异性结合的多肽，其筛选方法，鉴定和用途 |
| EA201891299A1 (ru) | 2016-01-08 | 2019-01-31 | Аимм Терапьютикс Б.В. | Терапевтические антитела к cd9 |
| CA3010313A1 (en) | 2016-01-13 | 2017-07-20 | Medimmune, Llc | Method of treating influenza a |
| JP7022067B2 (ja) * | 2016-01-14 | 2022-02-17 | メモリアル スローン ケタリング キャンサー センター | Ｆｏｘｐ３由来のペプチドに特異的なｔ細胞受容体様抗体 |
| AU2017239038B2 (en) | 2016-03-22 | 2024-06-27 | Bionomics Inc | Administration of an anti-LGR5 monoclonal antibody |
| KR102574810B1 (ko) | 2016-04-15 | 2023-09-08 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 습성 연령 관련 황반 변성의 치료를 위한 조성물 |
| WO2017218371A1 (en) * | 2016-06-14 | 2017-12-21 | Merck Sharp & Dohme Corp. | Anti-coagulation factor xi antibodies |
| CA3026474A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
| CN110291402B (zh) | 2016-06-27 | 2023-09-01 | 朱诺治疗学股份有限公司 | 鉴定肽表位的方法、结合此类表位的分子和相关用途 |
| MA45491A (fr) | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés |
| US11168148B2 (en) | 2016-09-07 | 2021-11-09 | The Regents Of The University Of California | Antibodies to oxidation-specific epitopes |
| CN118005799A (zh) * | 2016-09-23 | 2024-05-10 | 马伦戈治疗公司 | 包含λ轻链和κ轻链的多特异性抗体分子 |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| WO2018075621A1 (en) * | 2016-10-19 | 2018-04-26 | Vanderbilt University | Human orthopoxvirus antibodies and methods of use therefor |
| US20190324040A1 (en) * | 2016-10-29 | 2019-10-24 | University Of Miami | Zika virus antibodies |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| EP4613772A3 (en) | 2016-11-08 | 2025-12-24 | Regeneron Pharmaceuticals, Inc. | Antigen-binding proteins that antagonize leptin receptor |
| CA3041340A1 (en) * | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| TW201832778A (zh) * | 2016-11-10 | 2018-09-16 | 美商麥迪紐有限責任公司 | 對ａｓｃｔ２具有特異性的結合分子及其用途 |
| MA46952A (fr) | 2016-12-01 | 2019-10-09 | Regeneron Pharma | Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet |
| KR102599557B1 (ko) * | 2016-12-19 | 2023-11-07 | 펀다시오 프리바다 인스티튜시오 카탈라나 드 르세르카 아이 에스투디스 아반카츠 | Lif에 대한 항체 및 이의 용도 |
| JP2020506971A (ja) | 2017-02-08 | 2020-03-05 | ドラゴンフライ セラピューティクス， インコーポレイテッド | ナチュラルキラー細胞の活性化のための多重特異性結合タンパク質およびがんを処置するためのその治療的使用 |
| CN108456250B (zh) * | 2017-02-17 | 2025-11-28 | 恺兴生命科技(上海)有限公司 | 靶向il-13ra2的抗体及其应用 |
| WO2018151836A1 (en) | 2017-02-17 | 2018-08-23 | Fred Hutchinson Cancer Research Center | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
| SG11201907646YA (en) | 2017-02-20 | 2019-09-27 | Dragonfly Therapeutics Inc | Proteins binding her2, nkg2d and cd16 |
| CN110637031B (zh) * | 2017-03-04 | 2024-04-16 | 湘潭腾华生物科技有限公司 | 程序性死亡蛋白1(pd-1)的重组抗体及其用途 |
| JOP20180021A1 (ar) | 2017-03-16 | 2019-01-30 | Janssen Biotech Inc | الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| US10296425B2 (en) | 2017-04-20 | 2019-05-21 | Bank Of America Corporation | Optimizing data processing across server clusters and data centers using checkpoint-based data replication |
| WO2019018525A1 (en) * | 2017-07-20 | 2019-01-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | CHIMERIC ANTIGENIC RECEPTORS BINDING TO CD123 |
| SG10202111869SA (en) * | 2017-07-31 | 2021-11-29 | Trishula Therapeutics Inc | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies |
| WO2019036688A1 (en) * | 2017-08-18 | 2019-02-21 | Gritstone Oncology, Inc. | ANTIGEN BINDING PROTEINS TARGETING SHARED ANTIGENS |
| PL3703750T3 (pl) | 2017-11-01 | 2025-04-07 | Juno Therapeutics, Inc. | Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy |
| MA49911A (fr) | 2017-11-01 | 2020-06-24 | Juno Therapeutics Inc | Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b |
| MX2020004568A (es) | 2017-11-06 | 2020-10-05 | Juno Therapeutics Inc | Combinación de una terapia celular y un inhibidor de gamma secretasa. |
| US11034951B2 (en) | 2017-11-20 | 2021-06-15 | Nantbio, Inc. | mRNA display antibody library and methods |
| ES2969081T3 (es) * | 2017-11-20 | 2024-05-16 | Nantbio Inc | Una biblioteca de anticuerpos de presentación de ARNm y métodos |
| CN111542540A (zh) | 2017-12-18 | 2020-08-14 | 瑞泽恩制药公司 | 结合瘦蛋白受体和/或gp130的双特异性抗原结合分子及其使用方法 |
| CN117946267A (zh) | 2017-12-19 | 2024-04-30 | 瑟罗泽恩奥普瑞汀公司 | 抗卷曲蛋白抗体和使用方法 |
| AU2018393073B2 (en) | 2017-12-19 | 2025-09-18 | Surrozen Operating, Inc. | Wnt surrogate molecules and uses thereof |
| CA3085785A1 (en) | 2017-12-19 | 2019-06-27 | Surrozen, Inc. | Anti-lrp5/6 antibodies and methods of use |
| WO2019143884A1 (en) * | 2018-01-19 | 2019-07-25 | Vanderbilt University | Conserved hiv antibody clonotypes and methods of use |
| FI3749346T3 (fi) | 2018-02-08 | 2024-09-04 | Dragonfly Therapeutics Inc | Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät |
| PE20210375A1 (es) | 2018-02-08 | 2021-03-02 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales |
| MX2020008684A (es) | 2018-02-20 | 2020-12-07 | Dragonfly Therapeutics Inc | Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso. |
| JP7362636B2 (ja) | 2018-03-05 | 2023-10-17 | ヤンセン ファーマシューティカ エヌ．ベー． | 抗ｐｈｆ－タウ抗体及びその使用 |
| CR20200466A (es) | 2018-03-13 | 2020-11-11 | Tusk Therapeutics Ltd | Agentes anticuerpos anti-cd25 |
| HRP20250986T1 (hr) | 2018-04-06 | 2025-10-24 | Regeneron Pharmaceuticals, Inc. | Antitijelo agonista leptinskog receptora za upotrebu u povećanju koštane mase kod osobe koja pati od metaboličke disfunkcije ili hipoleptinemije |
| EP3553082A1 (en) * | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Brain natriuretic peptide engrafted antibodies |
| EP3553081A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Atrial natriuretic peptide engrafted antibodies |
| EP3553079A1 (en) * | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | C-type natriuretic peptide engrafted antibodies |
| US12036242B2 (en) | 2018-07-05 | 2024-07-16 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | CAR T cells that target B-cell antigens |
| US10954508B2 (en) * | 2018-07-08 | 2021-03-23 | Specifica Inc. | Antibody libraries with maximized antibody developability characteristics |
| CN110713537B (zh) * | 2018-07-13 | 2023-04-21 | 江苏怀瑜药业有限公司 | 一种sema4d抗体及其制备方法和应用 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| JP7482363B2 (ja) | 2018-08-08 | 2024-05-14 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及び腫瘍関連抗原に結合するタンパク質 |
| US12384851B2 (en) | 2018-08-08 | 2025-08-12 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use |
| CN112930393A (zh) | 2018-08-28 | 2021-06-08 | 福瑞德哈金森癌症研究中心 | 结合诱导的Notch信号传导的过继T细胞疗法的方法和组合物 |
| AU2019372331A1 (en) | 2018-11-01 | 2021-05-27 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen |
| CN109553680B (zh) * | 2018-12-12 | 2021-06-01 | 广州市第八人民医院 | 一种单克隆抗体ZKns4B8及其应用 |
| CN113226371B (zh) * | 2018-12-28 | 2025-05-30 | 协和麒麟株式会社 | 与TfR结合的双特异性抗体 |
| KR102736548B1 (ko) * | 2019-01-31 | 2024-12-02 | 난트바이오 인코포레이티드 | Mrna 디스플레이 항체 라이브러리 및 방법 |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| WO2020205775A1 (en) * | 2019-03-29 | 2020-10-08 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Antibodies against programmed cell death protein 1 (pd1) and uses thereof |
| WO2020219774A1 (en) * | 2019-04-24 | 2020-10-29 | Magenta Therapeutics, Inc. | Anthracycline antibody-drug conjugates and uses thereof |
| AU2020279224B2 (en) * | 2019-05-21 | 2024-12-05 | Novartis Ag | Trispecific binding molecules against BCMA and uses thereof |
| JP7744011B2 (ja) | 2019-06-07 | 2025-09-25 | スクライブ・セラピューティクス・インコーポレイテッド | 操作されたｃａｓｘシステム |
| WO2020247883A2 (en) * | 2019-06-07 | 2020-12-10 | Scribe Therapeutics Inc. | Deep mutational evolution of biomolecules |
| AU2020290579A1 (en) | 2019-06-14 | 2021-12-16 | Dana-Farber Cancer Institute, Inc. | Antibodies against MUC1 and methods of use thereof |
| AU2020300618A1 (en) * | 2019-07-02 | 2022-01-27 | Surrozen Operating, Inc. | Monospecific anti-frizzled antibodies and methods of use |
| WO2021011673A2 (en) * | 2019-07-16 | 2021-01-21 | Ming Jin | Neutralizing anti-amyloid beta antibodies for the treatment of alzheimer's disease |
| WO2021061829A1 (en) | 2019-09-23 | 2021-04-01 | Twist Bioscience Corporation | Variant nucleic acid libraries for crth2 |
| AU2020355027A1 (en) * | 2019-09-23 | 2022-04-21 | Twist Bioscience Corporation | Antibodies that bind CD3 Epsilon |
| IL292419A (en) * | 2019-10-24 | 2022-06-01 | Prometheus Biosciences Inc | Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof |
| CN115443140A (zh) * | 2020-04-02 | 2022-12-06 | 苏州恒康生命科学有限公司 | 人ror-1抗体和抗ror-1-car-t细胞 |
| BR112022021789A2 (pt) | 2020-04-27 | 2023-03-07 | Twist Bioscience Corp | Bibliotecas de ácido nucléico variantes para coronavírus |
| TW202208428A (zh) | 2020-05-06 | 2022-03-01 | 美商蜻蜓醫療公司 | 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質 |
| US20240002476A1 (en) * | 2020-05-20 | 2024-01-04 | The Trustees Of Columbia University In The City Of New York | Potent neutralizing antibodies against sars-cov-2, generation and uses thereof |
| CN111748033B (zh) * | 2020-05-27 | 2021-02-02 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | 一种与新型冠状病毒np蛋白结合的分离抗体、包含其的检测试剂盒 |
| EP4165171A4 (en) | 2020-06-12 | 2025-03-26 | Nkarta, Inc. | GENETICALLY MODIFIED NATURAL KILLER CELLS FOR CD70-DIRECTED CANCER IMMUNOTHERAPY |
| EP4154910A4 (en) * | 2020-06-30 | 2024-09-11 | Harbour Biomed (Shanghai) Co., Ltd | Binding protein having h2l2 and hcab structures |
| JP2023537386A (ja) * | 2020-08-10 | 2023-08-31 | インテグラル・モレキュラー・インコーポレイテッド | 抗体ライブラリーを作製するための方法および組成物ならびにそれから単離された抗体 |
| WO2022087393A1 (en) * | 2020-10-23 | 2022-04-28 | Icahn School Of Medicine At Mount Sinai | Sars-cov-2 antibodies and uses thereof |
| EP4256054A1 (en) | 2020-12-03 | 2023-10-11 | Scribe Therapeutics Inc. | Engineered class 2 type v crispr systems |
| KR20230118134A (ko) * | 2020-12-04 | 2023-08-10 | 이퀼리엄 아이엔씨 | CD6 high 세포 선택적 표적화 및 T eff 세포의 활성감소 방법 |
| MX2023008188A (es) * | 2021-01-11 | 2023-09-28 | Adimab Llc | Variante de dominios ch1 y variante de dominios cl modificadas geneticamente para el emparejamiento preferencial a cadenas y anticuerpos multiespecíficos que comprenden las mismas. |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| US20240327503A1 (en) * | 2021-03-12 | 2024-10-03 | Jimmy Dale GOLLIHAR | Sars-cov-2 neutralizing antibodies and uses thereof |
| US12258406B2 (en) | 2021-03-24 | 2025-03-25 | Twist Bioscience Corporation | Antibodies that bind CD3 Epsilon |
| US11655290B2 (en) | 2021-06-17 | 2023-05-23 | Atreca, Inc. | Anti-CSP antibodies |
| US20250319185A1 (en) * | 2021-07-12 | 2025-10-16 | Nkarta, Inc. | Bcma-directed cellular immunotherapy compositions and methods |
| WO2023004431A2 (en) * | 2021-07-23 | 2023-01-26 | The Trustees Of Columbia University In The City Of New York | Characterization of potent and broadly neutralizing monoclonal antibodies against sars-cov-2, its variants, and related coronaviruses and methods of use |
| JP2024527029A (ja) | 2021-07-29 | 2024-07-19 | セファロン リミティド ライアビリティ カンパニー | 抗ｐａｃａｐ抗体の組成物及び方法 |
| AU2022333321A1 (en) | 2021-08-27 | 2024-04-11 | Janssen Biotech, Inc. | Anti-psma antibodies and uses thereof |
| MX2024002479A (es) * | 2021-08-27 | 2024-05-28 | Janssen Biotech Inc | Radioconjugados anti-psma y usos de estos. |
| CA3228414A1 (en) * | 2021-09-02 | 2023-03-09 | Anthony DANIYAN | Anti-cd33 antibodies and uses thereof |
| CA3228546A1 (en) * | 2021-09-02 | 2023-03-09 | Memorial Sloan-Kettering Cancer Center | Antigen recognizing receptors targeting cd33 and uses thereof |
| WO2023034950A2 (en) * | 2021-09-03 | 2023-03-09 | Icahn School Of Medicine At Mount Sinai | Anti-hcmv antibodies and antigen-binding fragments thereof |
| US20230265217A1 (en) * | 2021-10-27 | 2023-08-24 | Twist Bioscience Corporation | Multispecific sars-cov-2 antibodies and methods of use |
| CN116333123A (zh) * | 2021-12-22 | 2023-06-27 | 宝船生物医药科技(上海)有限公司 | 抗tnfr2抗体及其用途 |
| CA3245432A1 (en) * | 2022-03-04 | 2023-09-07 | Coagulant Therapeutics Corporation | Human antibodies directed against activated protein C and their uses |
| WO2024077104A2 (en) * | 2022-10-04 | 2024-04-11 | Mink Therapeutics, Inc. | Fibroblast activation protein (fap) car-invariant natural killer t cells and uses thereof |
| WO2024194686A2 (en) | 2023-03-17 | 2024-09-26 | Oxitope Pharma B.V. | Anti-phosphocholine antibodies and methods of use thereof |
| CN116514998B (zh) * | 2023-05-12 | 2023-09-15 | 再少年(北京)生物科技有限公司 | 一种嵌合抗原受体、嵌合抗原受体-自然杀伤细胞及其在制备抗肿瘤药物中的应用 |
| US20250019426A1 (en) * | 2023-07-03 | 2025-01-16 | Uct Bioscience Co., Ltd. | Anti-grp78 antibodies and their uses |
| WO2025015320A2 (en) * | 2023-07-12 | 2025-01-16 | Phenomic Ai | Anti-cthrc1 t cell engagers and methods of using the same |
| WO2025049915A1 (en) * | 2023-08-31 | 2025-03-06 | Exelixis, Inc. | Ilt2 binding agents and uses thereof |
| US20250101101A1 (en) * | 2023-09-01 | 2025-03-27 | iTeos Belgium SA | Anti-trem2 antibodies and methods of use |
| WO2025081163A1 (en) * | 2023-10-13 | 2025-04-17 | GenCART, Inc. | Compositions for the treatment of cancer |
| US20250255980A1 (en) * | 2024-02-12 | 2025-08-14 | Mbrace Therapeutics, Inc. | Antibody-Drug Conjugates Against the Glucose-regulating Protein 78 (GRP78) |
| WO2025184137A1 (en) * | 2024-02-27 | 2025-09-04 | Adimab, Llc | Influenza antibodies and methods of use thereof |
| CN117986346B (zh) * | 2024-04-07 | 2024-07-26 | 中国人民解放军军事科学院军事医学研究院 | 一种tpo模拟肽及其应用 |
| WO2025217041A2 (en) * | 2024-04-09 | 2025-10-16 | Absos, Llc | Anti-april antibodies |
| CN120399078A (zh) * | 2025-05-08 | 2025-08-01 | 上海天泽云泰生物医药有限公司 | 靶向cd117的纳米抗体及其应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| JP3127158B2 (ja) | 1989-10-05 | 2001-01-22 | オプテイン，インコーポレイティド | 新規の遺伝子及びポリペチドの無細胞合成並びに単離 |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| US5866344A (en) | 1991-11-15 | 1999-02-02 | Board Of Regents, The University Of Texas System | Antibody selection methods using cell surface expressed libraries |
| US20030036092A1 (en) | 1991-11-15 | 2003-02-20 | Board Of Regents, The University Of Texas System | Directed evolution of enzymes and antibodies |
| ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| CA2229043C (en) | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| US5965408A (en) | 1996-07-09 | 1999-10-12 | Diversa Corporation | Method of DNA reassembly by interrupting synthesis |
| US6562594B1 (en) | 1999-09-29 | 2003-05-13 | Diversa Corporation | Saturation mutagenesis in directed evolution |
| GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
| GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
| US6153410A (en) | 1997-03-25 | 2000-11-28 | California Institute Of Technology | Recombination of polynucleotide sequences using random or defined primers |
| US20060122373A1 (en) | 1997-04-04 | 2006-06-08 | Millennium Pharmaceuticals, Inc. | Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof |
| ATE342358T1 (de) | 1997-04-04 | 2006-11-15 | Millennium Biotherapeutics Inc | Neue menschliche delta3-zusammensetzung und deren therapeutische und diagnostische verwendungen |
| DE69837601T2 (de) | 1997-05-14 | 2007-12-27 | Asahi Kasei Kabushiki Kaisha | Neuer hemmer der differentierung |
| JP2002523018A (ja) | 1998-07-27 | 2002-07-30 | アムジエン・インコーポレーテツド | デルタ関連ポリペプチド |
| WO2000009560A2 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US20020102613A1 (en) | 1999-05-18 | 2002-08-01 | Hoogenboom Hendricus Renerus Jacobus Mattheus | Novel Fab fragment libraries and methods for their use |
| GB0008419D0 (en) | 2000-04-05 | 2000-05-24 | Bioinvent Int Ab | A method for invitro molecular evolution of antibody function |
| AU784231B2 (en) | 2000-06-23 | 2006-02-23 | Schering Aktiengesellschaft | Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/tie receptor function and their use (II) |
| FR2816319B1 (fr) | 2000-11-08 | 2004-09-03 | Millegen | Utilisation d'adn polymerase mutagene pour la creation de mutations aleatoires |
| US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
| US20040253242A1 (en) * | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
| US20030022240A1 (en) | 2001-04-17 | 2003-01-30 | Peizhi Luo | Generation and affinity maturation of antibody library in silico |
| EP1438402A2 (en) | 2001-08-22 | 2004-07-21 | Galapagos Genomics N.V. | Modulators of bone homeostasis identified in a high-throughput screen |
| WO2003035842A2 (en) | 2001-10-24 | 2003-05-01 | Dyax Corporation | Hybridization control of sequence variation |
| WO2003099999A2 (en) | 2002-05-20 | 2003-12-04 | Abmaxis, Inc. | Generation and selection of protein library in silico |
| CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
| WO2004065416A2 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| WO2005023993A2 (en) * | 2003-09-09 | 2005-03-17 | Integrigen, Inc. | Methods and compositions for generation of germline human antibody genes |
| US7276585B2 (en) | 2004-03-24 | 2007-10-02 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
| US8048418B2 (en) | 2004-10-29 | 2011-11-01 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists |
| AU2006210660B2 (en) | 2005-02-01 | 2011-12-01 | Morphosys Ag | Libraries and methods for isolating antibodies |
| CA2627075A1 (en) | 2005-11-14 | 2007-05-18 | Bioren, Inc. | Antibody ultrahumanization by predicted mature cdr blasting and cohort library generation and screening |
| WO2007070671A2 (en) | 2005-12-16 | 2007-06-21 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with dll4 antagonists |
| US20090318308A1 (en) | 2006-05-30 | 2009-12-24 | Millegen | Highly diversified antibody libraries |
| US20080014196A1 (en) | 2006-06-06 | 2008-01-17 | Genentech, Inc. | Compositions and methods for modulating vascular development |
| AU2007319672B2 (en) | 2006-06-06 | 2011-06-30 | Genentech, Inc. | Anti-DLL4 antibodies and methods using same |
| SG174033A1 (en) | 2006-08-07 | 2011-09-29 | Regeneron Pharma | Therapeutic methods for treating vascular eye disorders with dll4 antagonists |
| HUE028379T2 (en) * | 2006-09-29 | 2016-12-28 | Oncomed Pharm Inc | Preparations and procedures for the diagnosis and treatment of cancer |
| US20080100597A1 (en) | 2006-10-25 | 2008-05-01 | Macrovision Corporation | Method and apparatus to improve playability in overscan areas of a TV display |
| NO347649B1 (no) * | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| WO2008091222A1 (en) | 2007-01-26 | 2008-07-31 | Bioinvent International Ab | Dll4 signaling inhibitors and uses thereof |
| GB0709333D0 (en) * | 2007-05-15 | 2007-06-20 | Smart Targeting Ltd | Binding protein |
| DK2356270T3 (da) | 2008-11-07 | 2016-12-12 | Fabrus Llc | Kombinatoriske antistofbiblioteker og anvendelser deraf |
-
2009
- 2009-11-04 DK DK09748671.6T patent/DK2356270T3/da active
- 2009-11-04 US US13/128,236 patent/US9403904B2/en not_active Expired - Fee Related
- 2009-11-04 JP JP2011535649A patent/JP5882058B2/ja not_active Expired - Fee Related
- 2009-11-04 EP EP09748671.6A patent/EP2356270B1/en active Active
- 2009-11-04 JP JP2011535651A patent/JP2012508017A/ja active Pending
- 2009-11-04 AU AU2009313551A patent/AU2009313551B2/en not_active Ceased
- 2009-11-04 US US13/128,219 patent/US9221902B2/en active Active
- 2009-11-04 WO PCT/US2009/063303 patent/WO2010054010A1/en not_active Ceased
- 2009-11-04 AU AU2009313560A patent/AU2009313560B2/en not_active Ceased
- 2009-11-04 EP EP09748672A patent/EP2356146A1/en not_active Withdrawn
- 2009-11-04 CA CA2742968A patent/CA2742968C/en not_active Expired - Fee Related
- 2009-11-04 WO PCT/US2009/063299 patent/WO2010054007A1/en not_active Ceased
- 2009-11-04 CA CA2742969A patent/CA2742969A1/en not_active Abandoned
-
2015
- 2015-08-10 JP JP2015157842A patent/JP2016040246A/ja active Pending
- 2015-12-04 US US14/959,940 patent/US10774138B2/en active Active
-
2016
- 2016-02-03 JP JP2016018531A patent/JP2016127850A/ja active Pending
- 2016-07-07 AU AU2016204719A patent/AU2016204719A1/en not_active Abandoned
-
2018
- 2018-03-06 AU AU2018201622A patent/AU2018201622A1/en not_active Abandoned
-
2020
- 2020-08-25 US US17/002,749 patent/US20200399359A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012508016A5 (OSRAM) | ||
| Shen et al. | Single variable domain-IgG fusion: a novel recombinant approach to Fc domain-containing bispecific antibodies | |
| JP2020536504A5 (OSRAM) | ||
| JP7668617B2 (ja) | ｐＨ依存的抗体の調製方法 | |
| Ylera et al. | Off-rate screening for selection of high-affinity anti-drug antibodies | |
| DK2606064T3 (en) | Methods for generating multispecific and multivalent antibodies | |
| JP6437913B2 (ja) | 複合体特異的抗体及び抗体断片並びにその使用 | |
| Peng et al. | Mining naive rabbit antibody repertoires by phage display for monoclonal antibodies of therapeutic utility | |
| CN1345334A (zh) | 对kdr特异的抗体及其应用 | |
| EP2938637A2 (en) | Multivalent binding protein compositions | |
| JPWO2019137548A5 (OSRAM) | ||
| CA2780221A1 (en) | Methods for affinity maturation-based antibody optimization | |
| CN101432015A (zh) | 功能性抗体 | |
| TW201242977A (en) | Tri-variable domain binding proteins and uses thereof | |
| IL276903B1 (en) | Bispecific egfr/cd16 antigen-binding protein | |
| CN116444667B (zh) | 一种靶向gdf15的全人源抗体及其应用 | |
| AU2018367622B2 (en) | mRNA display antibody library and methods | |
| Hust et al. | Antibody phage display | |
| Keller et al. | Selection of scFv antibody fragments binding to human blood versus lymphatic endothelial surface antigens by direct cell phage display | |
| WO2022157773A2 (en) | Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof | |
| GB2483998A (en) | Nucleic acid sequencing-based methods of analyzing affinities of libraries of binding compounds | |
| JPWO2019175368A5 (OSRAM) | ||
| WO2021084104A1 (en) | Tetravalent antibody molecules | |
| US20200141930A1 (en) | Method for determining the total amount and/or concentration of an analyte in the presence of a binding molecule as well as kits, compositions and uses relating thereto | |
| CN114891108B (zh) | 一种靶向bcma的全人源抗体及其应用 |